OrganoClick Past Earnings Performance
Past criteria checks 0/6
OrganoClick's earnings have been declining at an average annual rate of -12.2%, while the Chemicals industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 11.6% per year.
Key information
-12.2%
Earnings growth rate
-7.0%
EPS growth rate
| Chemicals Industry Growth | 32.9% |
| Revenue growth rate | 11.6% |
| Return on equity | -26.5% |
| Net Margin | -10.8% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Sentiment Still Eluding OrganoClick AB (publ) (STO:ORGC)
Mar 25
Earnings Update: OrganoClick AB (publ) (STO:ORGC) Just Reported And Analysts Are Trimming Their Forecasts
Feb 18OrganoClick (STO:ORGC) Seems To Use Debt Quite Sensibly
Jan 09Is OrganoClick AB (publ) (STO:ORGC) Potentially Undervalued?
May 11There's No Escaping OrganoClick AB (publ)'s (STO:ORGC) Muted Revenues Despite A 33% Share Price Rise
Apr 18Here's Why OrganoClick (STO:ORGC) Can Afford Some Debt
Jan 25Does OrganoClick (STO:ORGC) Have A Healthy Balance Sheet?
Sep 21OrganoClick AB (publ) (STO:ORGC) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 21Health Check: How Prudently Does OrganoClick (STO:ORGC) Use Debt?
Feb 20Is OrganoClick (STO:ORGC) Weighed On By Its Debt Load?
Apr 20Loss-Making OrganoClick AB (publ) (STO:ORGC) Expected To Breakeven In The Medium-Term
Mar 23Should You Take Comfort From Insider Transactions At OrganoClick AB (publ) (STO:ORGC)?
Feb 12
What Percentage Of OrganoClick AB (publ) (STO:ORGC) Shares Do Insiders Own?
Jan 05Analysts Expect Breakeven For OrganoClick AB (publ) (STO:ORGC) Before Long
Dec 18Calculating The Fair Value Of OrganoClick AB (publ) (STO:ORGC)
Dec 03Revenue & Expenses BreakdownBeta
How OrganoClick makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 146 | -16 | 37 | 7 |
| 30 Sep 23 | 140 | -28 | 39 | 7 |
| 30 Jun 23 | 128 | -33 | 41 | 7 |
| 31 Mar 23 | 126 | -40 | 42 | 8 |
| 31 Dec 22 | 115 | -44 | 43 | 8 |
| 30 Sep 22 | 111 | -36 | 42 | 8 |
| 30 Jun 22 | 112 | -35 | 42 | 8 |
| 31 Mar 22 | 113 | -32 | 41 | 7 |
| 31 Dec 21 | 110 | -33 | 40 | 8 |
| 30 Sep 21 | 110 | -31 | 38 | 7 |
| 30 Jun 21 | 108 | -29 | 38 | 7 |
| 31 Mar 21 | 104 | -24 | 34 | 6 |
| 31 Dec 20 | 96 | -24 | 33 | 5 |
| 30 Sep 20 | 93 | -23 | 31 | 5 |
| 30 Jun 20 | 89 | -23 | 30 | 5 |
| 31 Mar 20 | 86 | -23 | 30 | 5 |
| 31 Dec 19 | 85 | -20 | 29 | 4 |
| 30 Sep 19 | 84 | -18 | 29 | 4 |
| 30 Jun 19 | 84 | -18 | 29 | 4 |
| 31 Mar 19 | 82 | -18 | 30 | 4 |
| 31 Dec 18 | 78 | -20 | 31 | 3 |
| 30 Sep 18 | 78 | -23 | 32 | 3 |
| 30 Jun 18 | 78 | -24 | 32 | 4 |
| 31 Mar 18 | 75 | -26 | 31 | 4 |
| 31 Dec 17 | 75 | -28 | 31 | 4 |
| 30 Sep 17 | 69 | -26 | 34 | 3 |
| 30 Jun 17 | 62 | -26 | 36 | 2 |
| 31 Mar 17 | 51 | -28 | 38 | 1 |
| 31 Dec 16 | 40 | -29 | 39 | 0 |
| 30 Sep 16 | 38 | -28 | 37 | 0 |
| 30 Jun 16 | 37 | -25 | 35 | 0 |
| 31 Mar 16 | 33 | -22 | 33 | 0 |
| 31 Dec 15 | 32 | -20 | 31 | 0 |
| 30 Sep 15 | 30 | -17 | 28 | 0 |
| 30 Jun 15 | 27 | -16 | 26 | 0 |
| 31 Mar 15 | 24 | -16 | 26 | 0 |
| 31 Dec 14 | 21 | -16 | 24 | 0 |
| 30 Sep 14 | 20 | -15 | 23 | 0 |
| 31 Dec 13 | 8 | -9 | 15 | 0 |
Quality Earnings: ORGC is currently unprofitable.
Growing Profit Margin: ORGC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORGC is unprofitable, and losses have increased over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare ORGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORGC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-19%).
Return on Equity
High ROE: ORGC has a negative Return on Equity (-26.51%), as it is currently unprofitable.